Search results
Results from the WOW.Com Content Network
The 2010 DePuy Hip Replacement Recall was instituted when DePuy Orthopaedics, Inc., a division of Johnson and Johnson, recalled its ASR XL Acetabular metal-on-metal hip replacement system on August 24, 2010. [1] [2]
For 129 years, New Brunswick has served as the headquarters of J&J, America’s seventh most valuable public company. With consumer products from Band-Aids to baby powder, Neutrogena to Rogaine, Listerine to Visine, Aveeno to Tylenol and Sudafed to Splenda, Johnson & Johnson is the biggest and, according to multiple surveys, most admired ...
In many other countries, DePuy operates as a brand under the Johnson & Johnson Medical organization. [1] DePuy is currently the subject of more than 11,000 lawsuits related to its recall of faulty hip replacement systems, which lawyers and industry analysts estimate will cost parent company Johnson & Johnson billions of dollars to resolve. [2]
June 11, 2024 at 2:34 PM. By Jonathan Stempel. NEW YORK (Reuters) - Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its ...
The Supreme Court on Thursday rejected a nationwide settlement with OxyContin maker Purdue Pharma that would have shielded members of the Sackler family who own the company from civil lawsuits ...
Top executives from Bristol Myers Squibb, Johnson & Johnson, AbbVie and AstraZeneca, which have five of the 10 drugs chosen for the first wave of negotiations, described their newly informed views ...
Johnson & Johnson. / 40.49861°N 74.44361°W / 40.49861; -74.44361. Johnson & Johnson ( J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones ...
Two other allegedly faulty J&J products targeted by the plaintiffs lawyers were a device called a transvaginal mesh patch and an artificial hip implant. Suits involving these two products would soon end up competing with Risperdal for claims on the company’s reputation and treasury. Johnson & Johnson seemed to take the threats in stride.